Skip to main content
Premium Trial:

Request an Annual Quote

NIH, CDC to Receive Billions in Additional Funding Under Coronavirus Stimulus Bill

This story has been updated to reflect President Donald Trump's signing of the bill into law.

NEW YORK — The National Institutes of Health and the US Centers for Disease Control and Prevention will receive billions of dollars in new funding under a $2.2 trillion economic stimulus package aimed at bolstering the economy against the effects of the SARS-CoV-2 pandemic.

The spending package was approved by the US House of Representatives on Friday after clearing the US Senate earlier in the week. President Donald Trump signed it into law later on Friday.

The legislation — called the Coronavirus Aid, Relief, and Economic Security, or CARES, Act — will provide the NIH with $945.4 million in new funding. Specifically, the National Institute of Allergy and Infectious Diseases will get an additional $706 million, while the National Heart, Lung, and Blood Institute will receive an additional $103.4 million.

The National Institute of Biomedical Imaging and Bioengineering will receive an extra $60 million; the National Library of Medicine will receive an added $10 million; the National Center for Advancing Translational Sciences will get an additional $36 million; and the NIH's Office of the Director will receive an extra $30 million.

The NIH's current budget totals $41.46 billion.

The CDC, meanwhile, will receive a $4.3 billion infusion under the spending package, including $1.5 billion for grants and cooperative agreements with state and local governments.

CARES Act funding for the NIH and CDC is earmarked for preventing, preparing for, and responding to coronavirus domestically and internationally, and will be available to the agencies through Sept. 30, 2024.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more